Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors
David A. Nugiel, Kim Jacobs, Tabitha V. Worley et al. · Journal of Medicinal Chemistry · 1996
A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.
Cited by 107 works. doi:10.1021/jm960083n
Authors
- David A. Nugiel
- Kim Jacobs
- Tabitha V. Worley
- Mona Patel
- Robert F. III Kaltenbach
- Dayton T. Meyer
- Prabhakar K. Jadhav
- George V. De Lucca
- Thomas E. Smyser
- Ronald M. Klabe
- Lee T. Bacheler
- Marlene M. Rayner
- Steven P. Seitz
References
- Conserved Folding in Retroviral Proteases: Crystal Structure of Synthetic HIV-1 Protease
- N-methoxy-n-methylamides as effective acylating agents
- ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASE
- An Alternative Procedure for the Aluminum-Mediated Conversion of Esters to Amides
- L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor
- Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere
- An efficient method for the alkynylation of oxiranes using alkynyl boranes
- Present Status and Future Prospects for HIV Therapies
- Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl design